I'm not. I talked to him. He said it doesn't effect the uplist at all. The only thing it changes is he has to file a s1 and he can't file an s3. Which doesn't matter because he doesn't need to raise money besides drawing on the equity line when the price spikes so they can get eltropozine to the next phase studies. He said the biggest thing it has been is an embarrassment. Sometimes things happen outside your control and it was just a mistake. In a weird way it helps us because now they will have to be even more transparent which they already have done a good job of that.
News 
Market Data 
Discover 
